Table 2.
MDR P. aeruginosa susceptibility to ceftazidime/avibactam or ceftolozane/tazobactam in the presence of resistance to other antipseudomonal antimicrobial agents
| MDR resistance phenotype that included resistance to: | Isolates with resistance, n (%) | Isolates susceptible to CZA, n (%) | Isolates susceptible to C/T, n (%) |
|---|---|---|---|
| FEP | 198 (96.6) | 134 (67.7) | 122 (61.6) |
| TZP | 186 (90.7) | 126 (67.7) | 119 (63.9) |
| MEM | 185 (90.2) | 126 (68.1) | 140 (75.7) |
| CIP | 187 (91.2) | 142 (75.9) | 131 (70.1) |
| AMK | 119 (58.0) | 67 (56.3) | 55 (46.2) |
| GEN | 150 (73.2) | 98 (65.3) | 82 (54.7) |
| CAZ, FEP, TZP and MEM | 165 (80.5) | 106 (64.2) | 103 (62.4) |
| CAZ, FEP, TZP, MEM and CIP | 150 (73.2) | 91 (60.7) | 91 (60.7) |
| CAZ, FEP, TZP, MEM, CIP, GEN and AMK | 86 (42.0) | 38 (44.2) | 36 (41.9) |
AMK, amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; C/T, ceftolozane/tazobactam; CZA, ceftazidime/avibactam; FEP, cefepime; GEN, gentamicin; MEM, meropenem; TZP, piperacillin/tazobactam.